LBX Pharmacy Chain Joint Stock Company (603883.SS)
- Previous Close
20.37 - Open
20.10 - Bid 20.17 x --
- Ask 20.18 x --
- Day's Range
19.93 - 20.65 - 52 Week Range
11.90 - 28.38 - Volume
30,806,772 - Avg. Volume
27,624,416 - Market Cap (intraday)
15.331B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
34.19 - EPS (TTM)
0.59 - Earnings Date --
- Forward Dividend & Yield 0.33 (1.62%)
- Ex-Dividend Date Oct 10, 2024
- 1y Target Est
--
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; E-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products. In addition, it provides business, information technology consulting, technical, pharmaceutical consulting, clinic, and medical services. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.
www.lbxdrugs.com40,132
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 603883.SS
View MorePerformance Overview: 603883.SS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603883.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603883.SS
View MoreValuation Measures
Market Cap
15.48B
Enterprise Value
18.26B
Trailing P/E
34.53
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.70
Price/Book (mrq)
2.27
Enterprise Value/Revenue
0.82
Enterprise Value/EBITDA
18.40
Financial Highlights
Profitability and Income Statement
Profit Margin
2.02%
Return on Assets (ttm)
3.13%
Return on Equity (ttm)
8.05%
Revenue (ttm)
22.25B
Net Income Avi to Common (ttm)
448.44M
Diluted EPS (ttm)
0.59
Balance Sheet and Cash Flow
Total Cash (mrq)
2.42B
Total Debt/Equity (mrq)
70.12%
Levered Free Cash Flow (ttm)
1.86B